XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid‑in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balances (in shares) at Dec. 31, 2022   31,394,767      
Beginning balances at Dec. 31, 2022 $ 212,554 $ 3 $ 402,893 $ (2,057) $ (188,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   18,344      
Issuance of common stock upon exercise of stock options 129   129    
Vesting of early exercised options (in shares)   10,153      
Vesting of early exercised options 26   26    
Vesting of restricted stock units (in shares)   91,859      
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs (in shares)   1,618,613      
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs 19,407   19,407    
Stock‑based compensation 2,755   2,755    
Other comprehensive income (loss) 1,415     1,415  
Net income (loss) (6,674)       (6,674)
Ending balances (in shares) at Mar. 31, 2023   33,133,736      
Ending balances at Mar. 31, 2023 229,612 $ 3 425,210 (642) (194,959)
Beginning balances (in shares) at Dec. 31, 2022   31,394,767      
Beginning balances at Dec. 31, 2022 212,554 $ 3 402,893 (2,057) (188,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive income (loss) 1,561        
Net income (loss) 2,859        
Ending balances (in shares) at Sep. 30, 2023   33,340,216      
Ending balances at Sep. 30, 2023 246,663 $ 3 432,582 (496) (185,426)
Beginning balances (in shares) at Dec. 31, 2022   31,394,767      
Beginning balances at Dec. 31, 2022 $ 212,554 $ 3 402,893 (2,057) (188,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of early exercised options (in shares) 14,745        
Ending balances (in shares) at Dec. 31, 2023 33,437,296 33,437,296      
Ending balances at Dec. 31, 2023 $ 242,360 $ 3 437,132 195 (194,970)
Beginning balances (in shares) at Mar. 31, 2023   33,133,736      
Beginning balances at Mar. 31, 2023 229,612 $ 3 425,210 (642) (194,959)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   46,175      
Issuance of common stock upon exercise of stock options 257   257    
Vesting of early exercised options (in shares)   9,468      
Vesting of early exercised options 25   25    
Purchase of common stock under the employee stock purchase plan (in shares)   16,314      
Purchase of common stock under the employee stock purchase plan 186   186    
Stock‑based compensation 3,119   3,119    
Other comprehensive income (loss) (363)     (363)  
Net income (loss) (25,928)       (25,928)
Ending balances (in shares) at Jun. 30, 2023   33,205,693      
Ending balances at Jun. 30, 2023 206,908 $ 3 428,797 (1,005) (220,887)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   80,630      
Issuance of common stock upon exercise of stock options 368   368    
Vesting of early exercised options (in shares)   7,391      
Vesting of early exercised options 21   21    
Vesting of restricted stock units (in shares)   46,502      
Stock‑based compensation 3,396   3,396    
Other comprehensive income (loss) 509     509  
Net income (loss) 35,461       35,461
Ending balances (in shares) at Sep. 30, 2023   33,340,216      
Ending balances at Sep. 30, 2023 $ 246,663 $ 3 432,582 (496) (185,426)
Beginning balances (in shares) at Dec. 31, 2023 33,437,296 33,437,296      
Beginning balances at Dec. 31, 2023 $ 242,360 $ 3 437,132 195 (194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   30,888      
Issuance of common stock upon exercise of stock options 206   206    
Vesting of early exercised options (in shares)   3,411      
Vesting of early exercised options 13   13    
Vesting of restricted stock units (in shares)   132,458      
Stock‑based compensation 3,733   3,733    
Other comprehensive income (loss) (441)     (441)  
Net income (loss) 23,496       23,496
Ending balances (in shares) at Mar. 31, 2024   33,604,053      
Ending balances at Mar. 31, 2024 $ 269,367 $ 3 441,084 (246) (171,474)
Beginning balances (in shares) at Dec. 31, 2023 33,437,296 33,437,296      
Beginning balances at Dec. 31, 2023 $ 242,360 $ 3 437,132 195 (194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 260,271        
Vesting of early exercised options (in shares) 4,670        
Other comprehensive income (loss) $ 777        
Net income (loss) $ 64,495        
Ending balances (in shares) at Sep. 30, 2024 37,400,499 37,400,499      
Ending balances at Sep. 30, 2024 $ 422,447 $ 4 551,946 972 (130,475)
Beginning balances (in shares) at Mar. 31, 2024   33,604,053      
Beginning balances at Mar. 31, 2024 269,367 $ 3 441,084 (246) (171,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   166,155      
Issuance of common stock upon exercise of stock options 1,104   1,104    
Vesting of early exercised options (in shares)   3,411      
Vesting of early exercised options 13   13    
Vesting of restricted stock units (in shares)   11,490      
Purchase of common stock under the employee stock purchase plan (in shares)   20,384      
Purchase of common stock under the employee stock purchase plan 263   263    
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs (in shares)   3,367,003      
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs 99,608 $ 1 99,607    
Stock‑based compensation 4,622   4,622    
Other comprehensive income (loss) (83)     (83)  
Net income (loss) 55,031       55,031
Ending balances (in shares) at Jun. 30, 2024   37,172,496      
Ending balances at Jun. 30, 2024 429,925 $ 4 546,693 (329) (116,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   63,228      
Issuance of common stock upon exercise of stock options 381   381    
Vesting of early exercised options (in shares)   3,253      
Vesting of early exercised options 12   12    
Vesting of restricted stock units (in shares)   161,522      
Stock‑based compensation 4,860   4,860    
Other comprehensive income (loss) 1,301     1,301  
Net income (loss) $ (14,032)       (14,032)
Ending balances (in shares) at Sep. 30, 2024 37,400,499 37,400,499      
Ending balances at Sep. 30, 2024 $ 422,447 $ 4 $ 551,946 $ 972 $ (130,475)